Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pathways of Acetyl-CoA Metabolism Involved in the Reversal of Palmitate-Induced Glucose Production by Metformin and Salicylate.

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association·2016
Same author

The search for the mechanism of early sympathetic islet neuropathy in autoimmune diabetes.

Diabetes, obesity & metabolism·2014
Same author

Loss of coupling between calcium influx, energy consumption and insulin secretion associated with development of hyperglycaemia in the UCD-T2DM rat model of type 2 diabetes.

Diabetologia·2013
Same author

Attenuation of islet-specific T cell responses is associated with C-peptide improvement in autoimmune type 2 diabetes patients.

Clinical and experimental immunology·2013
Same author

Immunology of Diabetes Society T-Cell Workshop: HLA class II tetramer-directed epitope validation initiative.

Diabetes/metabolism research and reviews·2011
Same author

cJUN N-terminal kinase (JNK) activation mediates islet amyloid-induced beta cell apoptosis in cultured human islet amyloid polypeptide transgenic mouse islets.

Diabetologia·2011
Same journal

Acute Rejection Mediated by Preformed Anti-HLA-C Antibody in a Kidney Transplant Patient: A Case Report.

Transplantation proceedings·2026
Same journal

Liver Transplantation for Metastatic Neuroendocrine Tumors: A Single-Center Experience in a Brazilian Referral Center.

Transplantation proceedings·2026
Same journal

Analysis of the Cost of Maintaining Effective Donors and Nondonors of Organs and Tissues in Intensive Care Units.

Transplantation proceedings·2026
Same journal

Adolescence and Pediatric Heart Transplantation: Impact of Non-Adherence on Mortality: A Single-Center Experience.

Transplantation proceedings·2026
Same journal

Impact of Family-Based Care on the Outcome of Brain Death and Humanization in the Process of Multiple Organ Donation: Case Report.

Transplantation proceedings·2026
Same journal

Karnofsky Performance Status Is Associated with Patient and Graft Survival After Liver Retransplantation.

Transplantation proceedings·2026
See all related articles

Related Experiment Video

Updated: May 15, 2026

Longitudinal In Vivo Imaging and Quantification of Human Pancreatic Islet Grafting and Contributing Host Cells in the Anterior Eye Chamber
09:07

Longitudinal In Vivo Imaging and Quantification of Human Pancreatic Islet Grafting and Contributing Host Cells in the Anterior Eye Chamber

Published on: June 11, 2020

Rosiglitazone treatment does not decrease amyloid deposition in transplanted islets from transgenic mice expressing

J Udayasankar1, S Zraika, K Aston-Mourney

  • 1Division of Metabolism, Endocrinology and Nutrition, VA Puget Sound Health Care System and University of Washington, Seattle, Washington 98108, USA.

Transplantation Proceedings
|December 27, 2012
PubMed
Summary
This summary is machine-generated.

Rosiglitazone treatment did not reduce amyloid deposition or preserve beta-cell area in transplanted islets from human islet amyloid polypeptide (hIAPP) transgenic mice. This suggests rosiglitazone may not improve outcomes for islet transplantation involving amyloid-forming islets.

More Related Videos

Lentiviral Mediated Gene Silencing in Human Pseudoislet Prepared in Low Attachment Plates
11:24

Lentiviral Mediated Gene Silencing in Human Pseudoislet Prepared in Low Attachment Plates

Published on: May 14, 2019

Intraportal Transplantation of Pancreatic Islets in Mouse Model
09:01

Intraportal Transplantation of Pancreatic Islets in Mouse Model

Published on: May 5, 2018

Related Experiment Videos

Last Updated: May 15, 2026

Longitudinal In Vivo Imaging and Quantification of Human Pancreatic Islet Grafting and Contributing Host Cells in the Anterior Eye Chamber
09:07

Longitudinal In Vivo Imaging and Quantification of Human Pancreatic Islet Grafting and Contributing Host Cells in the Anterior Eye Chamber

Published on: June 11, 2020

Lentiviral Mediated Gene Silencing in Human Pseudoislet Prepared in Low Attachment Plates
11:24

Lentiviral Mediated Gene Silencing in Human Pseudoislet Prepared in Low Attachment Plates

Published on: May 14, 2019

Intraportal Transplantation of Pancreatic Islets in Mouse Model
09:01

Intraportal Transplantation of Pancreatic Islets in Mouse Model

Published on: May 5, 2018

Area of Science:

  • Endocrinology
  • Transplantation Biology
  • Diabetology

Background:

  • Human islet transplantation success is limited by long-term insulin independence decline.
  • Amyloid deposition in transplanted islets, particularly from human islet amyloid polypeptide (hIAPP) transgenic sources, causes beta-cell loss.
  • Previous studies indicated rosiglitazone reduces amyloid and preserves beta-cells in endogenous pancreatic tissue.

Purpose of the Study:

  • To investigate if rosiglitazone treatment mitigates amyloid deposition and subsequent beta-cell loss in transplanted islets.
  • To evaluate the efficacy of rosiglitazone in improving islet graft survival and function post-transplantation.

Main Methods:

  • Streptozotocin-induced diabetic mice received islets from hIAPP transgenic (T) or nontransgenic (NT) littermates.
  • Recipients were treated with either rosiglitazone (R) or plain water (C) for 12 weeks.
  • Graft histology assessed amyloid deposition and beta-cell area; plasma glucose monitored.

Main Results:

  • Amyloid was prevalent in all T islet grafts, irrespective of rosiglitazone treatment.
  • Rosiglitazone did not significantly alter the percentage of graft area occupied by amyloid.
  • Beta-cell area was reduced in T grafts compared to NT grafts, with no significant difference between TC and TR groups.

Conclusions:

  • Rosiglitazone treatment failed to decrease amyloid deposition in hIAPP transgenic islet grafts.
  • The drug did not prevent the associated beta-cell loss after islet transplantation.
  • Rosiglitazone is unlikely to improve outcomes when transplanting amyloid-forming islets.